Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.

Autor: Augsberger C; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany., Hänel G; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany., Xu W; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Pulko V; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Hanisch LJ; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Augustin A; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Challier J; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Hunt K; Research Unit Apoptosis in Hematopoietic Stem Cells (AHS), Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany., Vick B; Research Unit Apoptosis in Hematopoietic Stem Cells (AHS), Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany., Rovatti PE; Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milan, Italy., Krupka C; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany., Rothe M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany., Schönle A; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Sam J; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Lezan E; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Ducret A; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Ortiz-Franyuti D; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Walz AC; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Benz J; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Bujotzek A; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Lichtenegger FS; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Gassner C; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Carpy A; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Lyamichev V; Nimble Therapeutics, Madison, WI., Patel J; Nimble Therapeutics, Madison, WI., Konstandin N; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Tunger A; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.; National Center for Tumor Diseases, Partner Site Dresden, Dresden, Germany., Schmitz M; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.; National Center for Tumor Diseases, Partner Site Dresden, Dresden, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany., von Bergwelt-Baildon M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Spiekermann K; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Vago L; Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Jeremias I; Research Unit Apoptosis in Hematopoietic Stem Cells (AHS), Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; and.; Department of Pediatrics, Dr von Hauner Children's Hospital, Ludwig Maximilian University (LMU), Munich, Germany., Marrer-Berger E; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Umaña P; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Klein C; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Subklewe M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Blood [Blood] 2021 Dec 23; Vol. 138 (25), pp. 2655-2669.

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.

Autor: Bamopoulos SA; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. stefanos.bamopoulos@charite.de.; Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine Berlin, Berlin, Germany. stefanos.bamopoulos@charite.de., Batcha AMN; Institute for Medical Information Processing Biometry and Epidemiology, LMU Munich, Munich, Germany.; DIFUTURE (Data Integration for Future Medicine (DiFuture, www.difuture.de), LMU Munich, Munich, Germany., Jurinovic V; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Institute for Medical Information Processing Biometry and Epidemiology, LMU Munich, Munich, Germany., Rothenberg-Thurley M; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Janke H; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Ksienzyk B; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Philippou-Massier J; Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany., Graf A; Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany., Krebs S; Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany., Blum H; Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany., Schneider S; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Institute of Human Genetics, University Hospital, LMU Munich, Munich, Germany., Konstandin N; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Sauerland MC; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany., Görlich D; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany., Berdel WE; Department of Medicine, Hematology and Oncology, University of Münster, Münster, Germany., Woermann BJ; German Society of Hematology and Oncology, Berlin, Germany., Bohlander SK; Leukemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand., Canzar S; Gene Center, LMU Munich, Munich, Germany., Mansmann U; Institute for Medical Information Processing Biometry and Epidemiology, LMU Munich, Munich, Germany.; DIFUTURE (Data Integration for Future Medicine (DiFuture, www.difuture.de), LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Hiddemann W; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Braess J; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany., Spiekermann K; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Metzeler KH; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Herold T; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. tobias.herold@med.uni-muenchen.de.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. tobias.herold@med.uni-muenchen.de.; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), Munich, Germany. tobias.herold@med.uni-muenchen.de.

Publikováno v: Leukemia [Leukemia] 2020 Oct; Vol. 34 (10), pp. 2621-2634. Date of Electronic Publication: 2020 May 01.

Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia.

Autor: Stefańczyk, Sylwia A.^1,2 (AUTHOR) sylwia-anna.stefanczyk@med.uni-tuebingen.de, Hayn, Clara^1,2 (AUTHOR) haynclara@gmail.com, Heitmann, Jonas^1,2 (AUTHOR) jonas.heitmann@med.uni-tuebingen.de, Jung, Susanne^1,2,3 (AUTHOR) susanne.jung@med.uni-tuebingen.de, Zekri, Latifa^1,2 (AUTHOR), Märklin, Melanie^1,2 (AUTHOR) melanie.maerklin@med.uni-tuebingen.de

Publikováno v: Cancers. Jul2024, Vol. 16 Issue 13, p2455. 14p.

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.

Autor: Herold T; Department of Internal Medicine III, University of Munich, Germany tobias.herold@med.uni-muenchen.de.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Jurinovic V; Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Germany., Batcha AMN; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Germany., Bamopoulos SA; Department of Internal Medicine III, University of Munich, Germany., Rothenberg-Thurley M; Department of Internal Medicine III, University of Munich, Germany., Ksienzyk B; Department of Internal Medicine III, University of Munich, Germany., Hartmann L; Department of Internal Medicine III, University of Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Greif PA; Department of Internal Medicine III, University of Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Phillippou-Massier J; Institute of Biostatistics and Clinical Research, University of Münster, Germany, Krebs S; Institute of Biostatistics and Clinical Research, University of Münster, Germany, Blum H; Institute of Biostatistics and Clinical Research, University of Münster, Germany, Amler S; German Cancer Research Center (DKFZ), Heidelberg, Germany., Schneider S; Department of Internal Medicine III, University of Munich, Germany., Konstandin N; Department of Internal Medicine III, University of Munich, Germany., Sauerland MC; Institute of Biostatistics and Clinical Research, University of Munich, Germany., Görlich D; Institute of Biostatistics and Clinical Research, University of Munich, Germany., Berdel WE; Department of Medicine, Hematology and Oncology, University of Münster, Germany., Wörmann BJ; German Society of Hematology and Oncology, Berlin, Germany., Tischer J; Department of Internal Medicine III, University of Munich, Germany., Subklewe M; Department of Internal Medicine III, University of Munich, Germany., Bohlander SK; Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand., Braess J; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany., Hiddemann W; Department of Internal Medicine III, University of Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Metzeler KH; Department of Internal Medicine III, University of Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Mansmann U; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Germany., Spiekermann K; Department of Internal Medicine III, University of Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Haematologica [Haematologica] 2018 Mar; Vol. 103 (3), pp. 456-465. Date of Electronic Publication: 2017 Dec 14.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.